Lowered DHEA-S plasma levels in adult individuals with autistic disorder

The aim of this study was to determine for the first time neurosteroid levels, dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEA-S) in particular, in a group of adult patients with autistic disorder and compare these levels with normal healthy individuals. Levels of DHEA, DHEA-S and cortisol were compared between 15 adult drug-free patients with autistic disorder and 13 healthy controls. The Ritvo-Freeman Real-Life Rating Scale (RLRS) and the Overt Aggression Scale (OAS) were assessed as a measure of symptom severity. Significant lower DHEA-S levels were observed in the group with autistic disorder as compared to controls (p < 0.05). DHEA-S levels appear to be low in patients with autistic disorder and, while speculative, may play a role in the etiopathophysiology of the disorder.

[1]  G. Biggio,et al.  Clozapine, but not Haloperidol, Increases Brain Concentrations of Neuroactive Steroids in the Rat , 2001, Neuropsychopharmacology.

[2]  B. Freeman,et al.  A scale for rating symptoms of patients with the syndrome of autism in real life settings. , 1986, Journal of the American Academy of Child Psychiatry.

[3]  J. Endicott,et al.  The Overt Aggression Scale for the objective rating of verbal and physical aggression. , 1986, The American journal of psychiatry.

[4]  P. Robel,et al.  Neurosteroids, via sigma receptors, modulate the [3H]norepinephrine release evoked by N-methyl-D-aspartate in the rat hippocampus. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[5]  P. Maertens,et al.  Elevated plasma gamma-aminobutyric acid (GABA) levels in autistic youngsters: stimulus for a GABA hypothesis of autism. , 2002, Medical science monitor : international medical journal of experimental and clinical research.

[6]  J. Gilbert,et al.  Analysis of linkage disequilibrium in gamma-aminobutyric acid receptor subunit genes in autistic disorder. , 2000, American journal of medical genetics.

[7]  D. Chugani.  Role of altered brain serotonin mechanisms in autism , 2002, Molecular Psychiatry.

[8]  B. I. Cohen.  GABA-transaminase, the liver and infantile autism. , 2001, Medical hypotheses.

[9]  S. Mellon,et al.  Dehydroepiandrosterone: a potential signalling molecule for neocortical organization during development. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[10]  M. Serra,et al.  Neurosteroids and neuroactive drugs in mental disorders. , 2004, Life sciences.

[11]  E. Baulieu,et al.  Characterization and measurement of dehydroepiandrosterone sulfate in rat brain. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Ruth A. Carper,et al.  Unusual brain growth patterns in early life in patients with autistic disorder , 2001, Neurology.

[13]  A. Couteur,et al.  Autism Diagnostic Interview-Revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders , 1994, Journal of autism and developmental disorders.

[14]  Anderson Gm.  Monoamines in autism: an update of neurochemical research on a pervasive developmental disorder. , 1987 .

[15]  J. Buitelaar,et al.  Autism: current theories regarding its pathogenesis and implications for rational pharmacotherapy. , 2000, Paediatric drugs.

[16]  R. Verkes,et al.  Neurosteroids in depression: a review , 2002, Psychopharmacology.

[17]  D. Javitt,et al.  Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.

[18]  E. Baulieu,et al.  Dehydroepiandrosterone and dehydroepiandrosterone sulfate as neuroactive neurosteroids. , 1996, The Journal of endocrinology.

[19]  M. Sofroniew,et al.  Dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEAS) protect hippocampal neurons against excitatory amino acid-induced neurotoxicity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Poirier,et al.  Dehydroepiandrosterone (DHEA) protects hippocampal cells from oxidative stress-induced damage. , 1999, Brain research. Molecular brain research.

[21]  J. Lieberman,et al.  Olanzapine increases allopregnanolone in the rat cerebral cortex , 2000, Biological Psychiatry.

[22]  T. Steckler,et al.  Dehydroepiandrosterone – a neurosteroid , 2000, European journal of clinical investigation.

[23]  C. Montigny,et al.  Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via sigma receptors , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[24]  C. Gillberg,et al.  Epilepsy in autism and autisticlike conditions. A population-based study. , 1988, Archives of neurology.

[25]  P. Lapchak,et al.  Preclinical development of neurosteroids as neuroprotective agents for the treatment of neurodegenerative diseases. , 2001, International review of neurobiology.

[26]  F. Salek,et al.  DHEA and DHEA‐S: A Review , 1999, Journal of clinical pharmacology.

[27]  F. Marrosu,et al.  Paradoxical reactions elicited by diazepam in children with classic autism. , 1987, Functional neurology.

[28]  E. London,et al.  The neurosteroid dehydroepiandrosterone sulfate is an allosteric antagonist of the GABAA receptor , 1990, Brain Research.

[29]  W. Regelson,et al.  Dehydroepiandrosterone protects hippocampal neurons against neurotoxin-induced cell death: mechanism of action. , 1999, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[30]  F. Holsboer,et al.  Neuroactive steroids: molecular mechanisms of action and implications for neuropsychopharmacology , 2001, Brain Research Reviews.

[31]  Joseph T. Coyle,et al.  The Glutamatergic Dysfunction Hypothesis for Schizophrenia , 1996, Harvard review of psychiatry.

[32]  W. Leowattana.  DHEAS as a new diagnostic tool. , 2004, Clinica chimica acta; international journal of clinical chemistry.

[33]  M. Carlsson,et al.  Hypothesis: Is infantile autism a hypoglutamatergic disorder? Relevance of glutamate – serotonin interactions for pharmacotherapy , 1998, Journal of Neural Transmission.

[34]  C. Thiemermann,et al.  Superoxide dismutase mimetic with catalase activity, EUK-134, attenuates the multiple organ injury and dysfunction caused by endotoxin in the rat. , 2002, Medical science monitor : international medical journal of experimental and clinical research.

[35]  D. Cohen,et al.  Plasma androgens in autism , 1995, Journal of autism and developmental disorders.

[36]  N. Orentreich,et al.  Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. , 1984, The Journal of clinical endocrinology and metabolism.

[37]  Eric Schopler,et al.  Use of the childhood autism rating scale with autistic adolescents and adults. , 1989, Journal of the American Academy of Child and Adolescent Psychiatry.

[38]  E. London,et al.  Receptor binding and electrophysiological effects of Dehydroepiandrosterone sulfate, an antagonist of the GABAA receptor , 1991, Neuroscience.